# Tocilizumab for Renal Graft Inflammation

> **NCT02108600** · PHASE2 · COMPLETED · sponsor: **Flavio Vincenti** · enrollment: 33 (actual)

## Conditions studied

- Late Complication From Kidney Transplant

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02108600
- **Lead sponsor:** Flavio Vincenti
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-12-16
- **Final completion:** 2018-12-16
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02108600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02108600, "Tocilizumab for Renal Graft Inflammation". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02108600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*